Entrepreneurship & Implementation

OREXA’s lead indication is geriatric anorexia in supervised care settings: long-term care facilities, post-acute rehabilitation, and hospital nutrition services. Everything on this page is sized and argued for that indication.

We narrowed to it deliberately, from an earlier framing that led with pediatric malnutrition. Three reasons:

• Consent and monitoring. Residents in supervised care consent for themselves or through established surrogate processes, and intake, weight and adverse events are already recorded daily. A first-in-human study of a live engineered organism needs that density of observation.
• A readable endpoint. Appetite and energy intake in long-term care have validated instruments and a standard comparator. Pediatric growth outcomes take far longer to read out and confound with many other variables.
• A conventional regulatory entry point. Adult studies in a supervised setting are the normal route for a novel live biotherapeutic. Pediatric studies follow adult safety data; they do not precede it.

Poor appetite is close to the norm in long-term care, and the drugs used to treat it are the ones geriatric guidelines tell clinicians to avoid. That gap, a high-prevalence condition with no recommended pharmacological option, is the opening we are building into.

Prevalence. A systematic review of anorexia of aging cites prevalence ranging from up to 25% in community-dwelling older adults, to 62% in hospital populations, to 85% in nursing home populations (Cox et al., Nutrients, 2019). Even taking the low end of the long-term care range, the condition is routine rather than exceptional in the setting we are targeting.

Why it matters clinically. Sustained low intake in older adults drives weight loss, loss of muscle mass, impaired wound healing and slower recovery from acute illness. The appetite deficit is the upstream barrier: supplying better food does not help a resident who stops eating after a few bites.

Why current drugs are not the answer. The two most-used appetite stimulants are both on the list of medications to avoid in older adults:

• Megestrol acetate produces minimal gains in appetite and weight and no improvement in quality of life or survival, while carrying increased risk of thrombotic events, fluid retention and death. One estimate is that roughly 1 in 12 patients gains weight while roughly 1 in 23 has an adverse event leading to death (AAFP Choosing Wisely rationale).
• Megestrol and cyproheptadine are both listed in the AGS Beers Criteria as medications to avoid in older adults (same source).
• The Nutrients review found only megestrol had been tested in two double-blind placebo-controlled trials, with mixed and unreplicated results, and concluded that the findings “caution against the use of these medications” and that medication is “an unattractive option” given side-effect profiles and polypharmacy (Cox et al., 2019).

The unmet need, stated precisely. There is no appetite intervention for older adults in supervised care that is both supported by controlled evidence and compatible with geriatric prescribing guidance. High-calorie oral supplements raise weight but, per the Choosing Wisely rationale, have no demonstrated effect on quality of life, mood, function or survival. The need is for an intervention that acts without the systemic exposure that drives the current safety objections.

We interviewed clinicians, nursing and dietetic staff, caregivers and NGO program staff. Every design constraint below traces to something an interviewee said, not to something we assumed.

Method. Semi-structured interviews, 20 to 40 minutes, with an open prompt (“walk me through the last resident or patient you cared for who would not eat”) followed by probes on current practice, what they had tried, and what would make them adopt something new. We coded responses for recurring pain points and stopped adding new segments once themes repeated rather than diverged.

From insight to design requirement. Each interview theme produced a specific, testable product requirement:

The candidate is a live biotherapeutic: a food-grade bacterial chassis engineered to express a hydrolase that acts on lipid-derived signaling molecules in the gut lumen. The intended effect is local attenuation of a satiety signal, rather than systemic action on central appetite pathways.

Why local action is the core claim. Every documented objection to the existing drugs, sedation with cyproheptadine, thrombotic risk and adrenal suppression with megestrol, follows from systemic exposure. A product whose active component works in the lumen and is not meaningfully absorbed is targeting exactly the failure mode that keeps the current options off the recommended list. This is the claim the whole business case rests on, and it is therefore the claim that needs the strongest data. We do not yet have it; see Development status.

No approved product targets satiety signaling for geriatric anorexia. The competition is a set of options that are either guideline-discouraged, unsupported by outcome data, or aimed at a different part of the problem.

Where this leaves us. Our differentiation is not that we work better, because we have no comparative data and cannot claim that. It is that we are attempting a mechanism with a plausible route to acceptability in a population where the pharmacological options are actively discouraged. That is a real but narrower claim than “first-in-class appetite modulator,” and it is the one we can defend.

Our serviceable obtainable market in US long-term care is roughly $12M a year at a realistic early penetration, built up from facility and resident counts rather than down from a global market figure.

We have deliberately dropped the “1% of a $61B market” style of estimate. A share-of-a-large-number figure is not a serviceable market, and iGEM judges and investors both discount it. The build below can be checked line by line and argued with.

TAM, stated honestly as a ceiling. If every older adult with clinically significant poor appetite across US long-term care, post-acute and community settings were treated at this price, the US opportunity is in the low billions. We present this only as an upper bound, not as a number we expect to approach. For external context, the global oral clinical nutrition market was valued at $32.2B in 2024 and is forecast to reach $54B by 2034, a 5.5% CAGR (Global Market Insights). This is the adjacent category we would sell alongside, not a market we would capture.

Expansion layers, in the order we would pursue them.

1. US post-acute and rehabilitation: same buyer, same monitoring density, shorter stays.
2. Hospital nutrition services: higher prevalence (62% in hospital populations) but short length of stay limits a course-based product.
3. Community-dwelling older adults: largest population, hardest to reach, lowest monitoring; a later-stage market needing a different channel.
4. Lower-resource settings through NGO programs: the humanitarian case, but requires a cost structure we have not yet modeled.

We sell a course-based product to facilities, priced per resident-day, with licensing as the secondary route. A direct-to-caregiver subscription is a later-stage option, not a launch model.

Cost structure. Fermentation and lyophilization; encapsulation or matrix formulation; release testing and strain identity confirmation per lot; stability program; cold-chain-free distribution; and, the item most early business cases omit, the regulatory and quality system required for a live biotherapeutic, which dominates spend until launch.

Unit economics, not yet modeled. We do not have a cost of goods estimate. For a lyophilized live biotherapeutic, cost per dose is driven by fermentation yield, lyophilization cycle time and per-lot release testing, and at $1.50 per day the margin question is real rather than rhetorical. A first-pass COGS model is on the roadmap and should be in place before any investor conversation.

OREXA is a live biotherapeutic product regulated as a biologic by FDA’s Center for Biologics Evaluation and Research, and it requires an IND before any clinical study. Being a genetically modified strain adds requirements on top of the standard LBP package. This is a multi-year path, and the original “regulatory submission in Year 3” framing understated it substantially.

All requirements below are from FDA’s guidance on Early Clinical Trials with Live Biotherapeutic Products.

The IND is not optional. An IND is required where a study tests whether a product can diagnose, cure, mitigate, treat or prevent disease, explicitly including products otherwise marketed as foods or dietary supplements.

The engineered-strain surcharge. The guidance does not specifically address recombinant LBPs and states that such products are likely to raise additional considerations, with sponsors encouraged to contact FDA before submitting an IND. For a modified strain, the IND must document the modifications and the genetic construction, justify any antibiotic resistance genes, explain how attenuation was achieved and shown to be stable, and assess whether resistance could transfer to other microbes. For OREXA this means genetic stability over passage and in vivo, a containment or clearance strategy, and horizontal gene transfer assessment are IND-enabling work, not optional extras.

One consequence for our trial design. FDA notes that early studies in healthy volunteers can help identify common adverse events before testing in more vulnerable groups. Our target population, frail older adults in long-term care, is precisely such a group. We should expect to run a healthy-adult safety study first, which adds a phase our original roadmap did not contain.

Honest timeline. From current status to first-in-human is realistically three to five years, with IND-enabling work dominating. Nothing on our roadmap should imply commercial launch inside three years.

We have identified three candidate components and drafted a provisional patent outline covering composition of matter, method of use and manufacturing process. No application has been filed.

Freedom to operate is the open question. We have not run an FTO search. Enzyme-expressing engineered probiotics are an active field with substantial existing patent coverage, and the hydrolase class we are using is well characterized, which cuts both ways: easy to work with, harder to claim. An FTO search should precede any further patent spend, because discovering blocking art after filing is the expensive order to do this in.

Sequencing. Provisional filing is the cheap option that preserves a priority date for twelve months, but a provisional is only as good as the data supporting it. Filing before we have expression and stability data risks a priority date we cannot convert. Our order is: FTO search, then generate the supporting data, then file the provisional.

We have two prototype iterations and preliminary in vitro work. We have no efficacy data and no animal safety data. Stating this plainly is deliberate: overstated preliminary results are the fastest way to lose a judging panel’s confidence.

On the cytotoxicity result. Our earlier draft said “no cytotoxicity observed in preliminary assays” in a position that read as a safety claim. In vitro cytotoxicity screening says nothing about colonization behavior, immune response, genetic stability in vivo, or effects in frail older adults. We have moved it into the evidence table above so the claim sits at the strength the data supports.

Stakeholder traction, described accurately. Clinicians have expressed interest in pilot testing, care centers have asked about early access, and NGO contacts have discussed field feasibility. These are expressions of interest in conversation, not letters of intent, signed agreements or commitments of any kind. They indicate the problem is real and recognized; they are not commercial validation. Converting two or three into written letters of support, which cost a partner nothing and demonstrate genuine engagement, would materially strengthen this section.

Each gate is a stop condition, not a milestone to celebrate: failing Gate A means the local-action claim is wrong and the program should stop rather than proceed. The original Year 1 to Year 3 plan put commercial launch where Gate B now sits, which is roughly two years and one clinical phase optimistic.

Public acceptance, which we should not treat as a communications problem. A live genetically modified organism administered to frail older adults will attract scrutiny, and some of it will be legitimate. Our position should be that containment, genetic stability and reversibility are engineering requirements we meet before any clinical work, not messaging to be managed afterwards.

Pages opened for the figures and claims on this page.

Figures carried over from an earlier business case without a source, the $61B global malnutrition market, $14B pediatric nutrition, $21B geriatric nutrition and $73B probiotics figures, have been removed rather than cited, because we could not verify them.

The science behind the mechanism is on our Project Description page, and the conversations that shaped the clinical positioning are on our Clinical Expertise page.